摘要
目的研究分析醋酸泼尼松联合来氟米特治疗IgA肾病的临床观察及护理措施。方法选取2015年2月~2016年9月收治的100例IgA肾病患者为研究对象,随机分为对照组和实验组,每组患者各为50例。对照组患者给予醋酸泼尼松治疗,到12w后降至0.5mg/kg。实验组患者在此基础上给予来氟米特治疗,3d后降至20mg。实验组与对照组患者治疗时间均为3个月。2组患者均进行合理的护理措施,比较分析实验组与对照组患者的治疗效果。结果实验组患者的治疗有效率为94.0%显著高于对照组64.0%,差异具有统计学意义(P<0.05)。治疗后,实验组患者的24h蛋白尿水平为(0.541±0.322)g/L显著低于对照组(1.516±0.568)g/L,差异具有统计学意义(P<0.05)。实验组不良反应发生率为0%,对照组不良反应发生率为8.0%显著高于实验组,差异具有统计学意义(P<0.05)。结论醋酸泼尼松联合来氟米特治疗IgA肾病的临床疗效较为理想,能够显著提高治疗有效率,具有临床推广意义。
Objective To study and analyze the clinical observation and nursing measures of prednisone acetate combined leflunomide inthe treatment of IgA nephropathy.Methods100patients with IgA nephropathy treated in our hospital from February2015to September2016wererandomly divided into the control group and the experimental group,with50patients in each group.Patients in the control group were treated withprednisone and dropped to0.5mg/kg after12weeks.The patients in the experimental group were treated with leflunomide and dropped to20mgafter3days.The patients in the experimental group and the control group were treated for3months.The two groups of patients were given reasonablenursing measures,and compared the treatment effect.Results The effective rate of treatment in the experimental group was94.0%,significantlyhigher than that in the control group(64.0%),with statistical difference(P<0.05).After treatment,the level of24hours proteinuria in theexperimental group was(0.541±0.322)g/L,significantly lower than that of the control group(1.516±0.568)g/L,with statistical difference(P<0.05).The adverse reaction rate of the experimental group was0%,and that of the control group was8%,with statistical difference(P<0.05).ConclusionPrednisone acetate combined leflunomide was effective in the treatment of IgA nephropathy,and can significantly improve the efficiency of treatment,and has clinical significance.
作者
林婉清
张月华
王辉
LIN Wan-qing;ZHANG Yue-hua;WANG Hui(Department of Armed Police Corps, Zhejiang Jiaxing Hospital, Jiaxing 314000, China)
出处
《中国生化药物杂志》
CAS
2017年第9期295-296,共2页
Chinese Journal of Biochemical Pharmaceutics